A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer

Table 3 Description of patient ascites samples used for quantitative Real-Time PCR analysis

Sample no.	Diagnosis	Silverberg grade	FIGO stage	Treatment	Age	Survival
Chemonaive
1	Serous Cystadenoma/ Early Serous Borderline	NA	NA	None	64	NA
2	Serous Cystadenocarcinoma	NA	III	None	65	1 year 5 months^a
3	Serous Papillary Carcinoma	G3	NA	None	NA	NA
4	Papillary Serous Cystadenocarcinoma	G3	IIIc	None	48	1 year 6 months^a
5	Serous Cystadenocarcinoma NOS	G3	IIIa	None	51	1 year 3 months^a
6	Serous Cystadenocarcinoma NOS	G3	NA	None	71	1 year 1 month^a
Recurrent
1	Serous Cystadenocarcinoma NOS	G3	IIc	Carboplatin and Paclitaxel 2 Cycles	64	5 months until death
2	Adenocarcinoma NOS	NA	IV	Carboplatin and Paclitaxel 6 Cycles	67	2 years 8 months until death
3	Serous Cystadenocarcinoma NOS	G3	IIIc	Carboplatin/Paclitaxel/ Bevacizumab-VGEF Inhibitor (ICON7 Trial) 18 Cycles	55	5 years 6 months until death
4	Papillary Serous Cystadenocarcinoma	G3	IIIc	Carboplatin and Paclitaxel 6 Cycles	59	3 years 2 months until death
4	Papillary Serous Cystadenocarcinoma	G3	IIIc	Gemicitabine and Cisplatin	59	3 years 2 months until death
5	Papillary Serous Cystadenocarcinoma	G3	IIIc	Carboplatin/Paclitaxel/BIBF1120- Angiogenesis Inhibitor (OVAR12 Study)	46	3 years 11 months ALC
6	Serous Cystadenocarcinoma NOS	G3	IV	Bevacizumab 1 cycle	57	4 years 3 months
				Paclitaxel and Cisplatin 6 cycles		ALC
				Doxorubicin Pegylated Liposomal 6 cycles		ALC

ISSN: 1476-4598